StreetInsider.com News Articles

Sellas presents preclinical SLS009 pancreatic cancer data at AACR

Fri, 25 Sep 2026 13:00:19 -0400

SELLAS Life Sciences Group (NASDAQ: SLS) presented preclinical data at the American Association for Cancer Research Conference on Pancreatic Cancer in San Diego, showing activity of its CDK9 inhibitor SLS009 (tambiciclib) in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC).

The studies, conducted with researchers at the University of Wisconsin–Madison, tested SLS009 in MYC-amplified PDAC models, including one resistant to the RAS inhibitor daraxonrasib, and in combination with the BET inhibitor ZEN3694.

In the daraxonrasib-resistant model, SLS009 at 200 nM induced 17.9% apoptosis and 14.5% necrosis, compared with 2.8% apoptosis and 2.7% necrosis for daraxonrasib alone. Combining the two agents increased apoptosis

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

Fri, 25 Sep 2026 13:00:00 -0400

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model -
Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -
SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology -

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

Fri, 25 Sep 2026 13:00:00 -0400

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model -
Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -
SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology -

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a

Communities Finalise Life Plans Alongside Renewed Shuar Agreements as Warintza Continues to Advance De-Risking Activities

Thu, 10 Sep 2026 07:00:00 -0400

HIGHLIGHTS OF THE PRESS RELEASE:

Warints and Yawi communities finalise their respective Life Plans, which recognise mining as an important resource supporting their long-term development objectives, alongside renewal of the Company’s cooperation agreements with FISCH and PSHA
Continued permitting progress following technical approval of the EIA, with multiple regulatory processes advancing in parallel
Strong progress across the technical studies, advancing the next phase of development at Warintza, supported by a strong Balance Sheet

QUITO, Ecuador, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (“Solaris” or

Communities Finalise Life Plans Alongside Renewed Shuar Agreements as Warintza Continues to Advance De-Risking Activities

Thu, 10 Sep 2026 07:00:00 -0400

HIGHLIGHTS OF THE PRESS RELEASE:

Warints and Yawi communities finalise their respective Life Plans, which recognise mining as an important resource supporting their long-term development objectives, alongside renewal of the Company’s cooperation agreements with FISCH and PSHA

Continued permitting progress following technical approval of the EIA, with multiple regulatory processes advancing in parallel

Strong progress across the technical studies, advancing the next phase of development at Warintza, supported by a strong Balance Sheet

QUITO, Ecuador, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (“Solaris” or

SELLAS Life Sciences Group, Inc. (SLS) Reports In-Line Q2 EPS

Tue, 11 Aug 2026 16:36:11 -0400

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05).
For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

Form 8-K SELLAS Life Sciences For: Aug 11

Tue, 11 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26905708.html

Form 8-K SELLAS Life Sciences For: Aug 11

Tue, 11 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26905708.html

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

Form 10-Q SELLAS Life Sciences For: Jun 30

Tue, 11 Aug 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260811/26905439.html

Form 10-Q SELLAS Life Sciences For: Jun 30

Tue, 11 Aug 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260811/26905439.html

Form SCHEDULE 13G SELLAS Life Sciences Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:58:00 -0400
si-local-file:///var/storage/secattach/20260807/26889206.html

Form SCHEDULE 13G SELLAS Life Sciences Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:58:00 -0400
si-local-file:///var/storage/secattach/20260807/26889206.html

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them

Tue, 04 Aug 2026 09:15:00 -0400

Issued on behalf of Salazar Resources Limited

In less than a month, Salazar Resources defined a 1.5 km by 0.5 km copper-gold porphyry mineralized footprint at Monja, received a government fee exemption that materially improves the economics of exploration-stage companies across Ecuador, and watched El Domo -- the mine under construction in which it holds a 25% carried interest -- have its after-tax NPV confirmed at US$573 million. Then, on July 24, Canada and Ecuador signed a free trade agreement. The four events are distinct. The story they tell together is not.

VANCOUVER, British Columbia,